# A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT06839872** · PHASE2 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT06839872
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-30
- **Primary completion:** 2028-07-28
- **Final completion:** 2030-07-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** AstraZeneca has made the decision to cancel the trial.
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06839872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06839872, "A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06839872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*